We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RVTY Unveils Signals BioDesign for Faster Molecular Cloning & R&D Data
Read MoreHide Full Article
Key Takeaways
RVTY introduced Signals BioDesign, a cloud platform to simplify molecular cloning workflows for biotech teams.
The solution integrates cloning methods with collaboration tools to speed therapy development timelines.
Signals BioDesign supports up to 1,000 constructs and features an AI-ready infrastructure for innovation.
Revvity, Inc. (RVTY - Free Report) announced the launch of Signals BioDesign, a cloud-based molecular cloning platform, under its Revvity Signals Software division. Designed for biotech and pharmaceutical R&D teams, the solution aims to simplify complex cloning workflows while supporting scalable and collaborative development within a single digital ecosystem. By integrating cloning techniques with enterprise-level collaboration tools, Signals BioDesign overcomes the limitations of traditional desktop applications and complicated systems.
Management noted that Signals BioDesign meets a critical demand for molecular biology teams developing the next-generation antibody, cell and gene therapies. The platform equips researchers with streamlined, enterprise-level collaboration and centralized construct management, avoiding the burden of complex systems. By connecting with the Signals One platform, the solution is designed to help teams speed up development timelines and deliver critical therapies to patients faster.
Likely Trend of RVTY Stock Following the News
Shares of Revvity have lost 0.7% since the announcement on Thursday. In the year-to-date period, shares of the company have lost 7.2% compared with the industry’s 10.7% decline and the S&P 500’s 0.7% fall.
In the long run, the launch of Signals BioDesign is a strong positive for Revvity, as it enhances its software portfolio with a scalable, cloud-native solution tailored to growing biologics R&D needs and bringing life-saving therapies to market faster. By enabling faster construct design, seamless collaboration and integration within the Signals One ecosystem, the platform strengthens customer value and stickiness among biotech and pharma clients.
Its AI-ready infrastructure positions Revvity for innovation in predictive biology, supporting long-term growth. As biologics research grows more complex, solutions like Signals BioDesign can drive higher software adoption, recurring revenues and deeper enterprise penetration in an expanding biologics market.
RVTY currently has a market capitalization of $10.04 billion.
Image Source: Zacks Investment Research
More on the Launch
Signals BioDesign offers an end-to-end solution for designing therapeutic constructs across essential cloning methodologies, including Golden Gate, Gibson assembly and restriction/ligation workflows. It also integrates critical capabilities, such as primer design, Sanger sequencing analysis and protein translation into a single, easy-to-use interface. With support for high-throughput combinatorial cloning of up to 1,000 constructs, the platform empowers researchers to accelerate design cycles, collaborate and eliminate fragmented data silos.
What sets Signals BioDesign apart is its cloud-native architecture. It enables real-time collaboration, centralized bio-sequence libraries, duplicate detection and robust access controls. Its multi-tenant SaaS model reduces administrative burden and mitigates compliance risks tied to software licensing, making it a scalable solution for modern research organizations. The platform is built with AI-ready data infrastructure, positioning teams to leverage future machine learning applications for sequence optimization and predictive design.
Revvity will showcase Signals BioDesign’s offering at the Bio-IT World Conference & Expo on May 19-21 in Boston, MA.
Industry Prospects Favoring the Market
Going by the data provided by Persistence Market Research, the molecular cloning market is valued at $6 billion in 2026 and is expected to witness a CAGR of 5.4% through 2033.
Factors like the rising gene and cell therapy pipelines, growth in recombinant protein production, advancements in automation and miniaturization, and the emergence of synthetic biology and cell-free systems are boosting the market’s growth.
Other News
In February, Revvity announced the introduction of several discovery platforms and technologies in high-content imaging, detection and automation to speed up drug discovery processes at SLAS2026. The new offerings include the Opera Phenix OptIQ high-content screening system, the EnVision Nexus One multimode plate reader and the AssayMate workstation, along with other latest solutions covering sample preparation, screening, advanced imaging and laboratory automation.
In January, RVTY announced a collaboration with Eli Lilly and Company to make Eli Lilly’s TuneLab predictive models available through the Revvity Signals platform. The partnership expands on RVTY’s Signals Xynthetica platform, establishing a scalable and federated framework to develop drugs through AI-driven research and innovation.
Currently, Revvity carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Pacific Biosciences of California (PACB - Free Report) , Phibro Animal Health (PAHC - Free Report) and GE HealthCare Technologies (GEHC - Free Report) .
Pacific Biosciences of California, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted loss of 12 cents per share, which surpassed the Zacks Consensus Estimate by 36.8%. Revenues of $44.6 million beat the Zacks Consensus Estimate by 9.4%. You can see the complete list of today’s Zacks #1 Rankstocks here.
PACB has an estimated earnings recession rate of 1.9% compared with the industry’s 13.5% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 27.7%.
Phibro Animal Health, currently carrying a Zacks Rank #2 (Buy), reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
GE HealthCare Technologies, currently carrying a Zacks Rank #2, reported fourth-quarter 2025 adjusted EPS of $1.44, which surpassed the Zacks Consensus Estimate by 0.7%. Revenues of $5.7 billion beat the Zacks Consensus Estimate by 1.9%.
GEHC has an estimated long-term earnings growth rate of 9.1% compared with the industry’s 12.2% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 7.5%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
RVTY Unveils Signals BioDesign for Faster Molecular Cloning & R&D Data
Key Takeaways
Revvity, Inc. (RVTY - Free Report) announced the launch of Signals BioDesign, a cloud-based molecular cloning platform, under its Revvity Signals Software division. Designed for biotech and pharmaceutical R&D teams, the solution aims to simplify complex cloning workflows while supporting scalable and collaborative development within a single digital ecosystem. By integrating cloning techniques with enterprise-level collaboration tools, Signals BioDesign overcomes the limitations of traditional desktop applications and complicated systems.
Management noted that Signals BioDesign meets a critical demand for molecular biology teams developing the next-generation antibody, cell and gene therapies. The platform equips researchers with streamlined, enterprise-level collaboration and centralized construct management, avoiding the burden of complex systems. By connecting with the Signals One platform, the solution is designed to help teams speed up development timelines and deliver critical therapies to patients faster.
Likely Trend of RVTY Stock Following the News
Shares of Revvity have lost 0.7% since the announcement on Thursday. In the year-to-date period, shares of the company have lost 7.2% compared with the industry’s 10.7% decline and the S&P 500’s 0.7% fall.
In the long run, the launch of Signals BioDesign is a strong positive for Revvity, as it enhances its software portfolio with a scalable, cloud-native solution tailored to growing biologics R&D needs and bringing life-saving therapies to market faster. By enabling faster construct design, seamless collaboration and integration within the Signals One ecosystem, the platform strengthens customer value and stickiness among biotech and pharma clients.
Its AI-ready infrastructure positions Revvity for innovation in predictive biology, supporting long-term growth. As biologics research grows more complex, solutions like Signals BioDesign can drive higher software adoption, recurring revenues and deeper enterprise penetration in an expanding biologics market.
RVTY currently has a market capitalization of $10.04 billion.
Image Source: Zacks Investment Research
More on the Launch
Signals BioDesign offers an end-to-end solution for designing therapeutic constructs across essential cloning methodologies, including Golden Gate, Gibson assembly and restriction/ligation workflows. It also integrates critical capabilities, such as primer design, Sanger sequencing analysis and protein translation into a single, easy-to-use interface. With support for high-throughput combinatorial cloning of up to 1,000 constructs, the platform empowers researchers to accelerate design cycles, collaborate and eliminate fragmented data silos.
What sets Signals BioDesign apart is its cloud-native architecture. It enables real-time collaboration, centralized bio-sequence libraries, duplicate detection and robust access controls. Its multi-tenant SaaS model reduces administrative burden and mitigates compliance risks tied to software licensing, making it a scalable solution for modern research organizations. The platform is built with AI-ready data infrastructure, positioning teams to leverage future machine learning applications for sequence optimization and predictive design.
Revvity will showcase Signals BioDesign’s offering at the Bio-IT World Conference & Expo on May 19-21 in Boston, MA.
Industry Prospects Favoring the Market
Going by the data provided by Persistence Market Research, the molecular cloning market is valued at $6 billion in 2026 and is expected to witness a CAGR of 5.4% through 2033.
Factors like the rising gene and cell therapy pipelines, growth in recombinant protein production, advancements in automation and miniaturization, and the emergence of synthetic biology and cell-free systems are boosting the market’s growth.
Other News
In February, Revvity announced the introduction of several discovery platforms and technologies in high-content imaging, detection and automation to speed up drug discovery processes at SLAS2026. The new offerings include the Opera Phenix OptIQ high-content screening system, the EnVision Nexus One multimode plate reader and the AssayMate workstation, along with other latest solutions covering sample preparation, screening, advanced imaging and laboratory automation.
In January, RVTY announced a collaboration with Eli Lilly and Company to make Eli Lilly’s TuneLab predictive models available through the Revvity Signals platform. The partnership expands on RVTY’s Signals Xynthetica platform, establishing a scalable and federated framework to develop drugs through AI-driven research and innovation.
Revvity Inc. Price
Revvity Inc. price | Revvity Inc. Quote
RVTY’s Zacks Rank & Key Picks
Currently, Revvity carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Pacific Biosciences of California (PACB - Free Report) , Phibro Animal Health (PAHC - Free Report) and GE HealthCare Technologies (GEHC - Free Report) .
Pacific Biosciences of California, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted loss of 12 cents per share, which surpassed the Zacks Consensus Estimate by 36.8%. Revenues of $44.6 million beat the Zacks Consensus Estimate by 9.4%. You can see the complete list of today’s Zacks #1 Rankstocks here.
PACB has an estimated earnings recession rate of 1.9% compared with the industry’s 13.5% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 27.7%.
Phibro Animal Health, currently carrying a Zacks Rank #2 (Buy), reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
GE HealthCare Technologies, currently carrying a Zacks Rank #2, reported fourth-quarter 2025 adjusted EPS of $1.44, which surpassed the Zacks Consensus Estimate by 0.7%. Revenues of $5.7 billion beat the Zacks Consensus Estimate by 1.9%.
GEHC has an estimated long-term earnings growth rate of 9.1% compared with the industry’s 12.2% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 7.5%.